Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: A clinicopathologic study of 65 cases

American Journal of Surgical Pathology

Volumn 22, Issue 10, 1998, Pages 1192-1202

  Vergier, B ^b,c   Beylot Barry, M ^b   Pulford, K ^a   Michel, P ^d   Bosq, J ^b   De Muret, A ^b   Beylot, C ^d   Delaunay, M M ^b   Avril, M F ^b   Dalac, S ^b   Bodemer, C ^b   Joly, P ^b   Groppi, A ^d   De Mascarel, A ^d   Bagot, M ^b   Mason, D Y ^a   Wechsler, J ^b   Merlio, J P ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b Fr Stud Grp of Cutaneous Lymphoma   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d NONE

Author keywords

ALK; CD30; CD30+ lymphoproliferative disorders; Cutaneous lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD15 ANTIGEN; CD30 ANTIGEN; CHLORMETHINE; EPITHELIAL MEMBRANE ANTIGEN; INTERFERON; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; EXCISION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PROGNOSIS; SKIN LYMPHOMA; STATISTICAL ANALYSIS; ULTRAVIOLET A RADIATION;

ANTIGENS, CD30; CA-15-3 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TESTS, ROUTINE; DNA, NEOPLASM; EVALUATION STUDIES; FEMALE; FRANCE; HUMANS; LYMPHOMA, LARGE-CELL; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN DISEASES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031663294     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199810000-00004     Document Type: Article

References (47)

1. Agnarsson BA, Kadin ME. Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases. Am J Surg Pathol 1988;12:264-74.
2. Banerjee S, Heald J, Harris M. Twelve cases of Ki-1 positive anaplastic large-cell lymphoma of the skin. J Clin Pathol 1991; 44:119-25.
3. Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD-30+ large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. Cancer 1993;71:2097-104.
4. Beljaards RC, Meijer CJLM, Scheffer E. Differential diagnosis of cutaneous large cell lymphomas using monoclonal antibodies in paraffin-embedded skin biopsies. Am J Dermatopathol 1991;13: 342-9.
5. Beljaards RC, Meijer CJLM, Scheffer E, et al. Prognostic significance of CD30 (KI-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. Am J Pathol 1989;135: 1169-78.
6. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol 1992;126:596-602.
7. Beylot-Barry M, Lamant L, Vergier B, et al. Detection of t(2;5)(p23:q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD-30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol 1996;149:483-92.
8. Beylot-Barry M, Vergier B, De Mascarel A, Beylot C, Merlio JP. p53 oncoprotein expression in cutaneous lymphoproliferations. A study of 51 cases. Arch Dermatol 1995;131:1019-25.
9. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:3118-22.
10. Carbone A, Gloghini A, Volpe R. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas. Cancer 1992;70: 2691-8.
11. Cerroni L, Rieger E, Hödl S, et al. Clinicopathologic and immunologic features associated with transformation of mycosis lungoïdes to large cell lymphoma. Am J Surg Pathol 1992;16:543-52.
12. De Bruin PC, Beljaards RC, Van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 1993;23:127-35.
13. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2:5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996;87: 3437-41.
14. Delsol G, Al Saati T, Gatter K, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas: diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988;130:59-70.
15. Delsol G, Blancher A, Al Saati T, et al. Antibody BNH.9 detects red blood cell-related antigens on anaplastic large cell (CD 30+) lymphomas. Br J Cancer 1991;64:321-6.
16. Durkop H, Latza U, Hummel M. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421-7.
17. Feuerstein N, Mond JJ. "Numatrin," a nuclear matrix protein associated with induction of proliferation in B lymphocytes. J Biol Chem 1987;262:11389-97.
18. Feuerstein N, Spiegel S, Mond JJ. The nuclear matrix protein, numatrin (B23), is associated with growth factor-induced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T-cell antigen receptor antibody. J Cell Biol 1988;107:1629-42.
19. Filippa DA, Ladanyi M, Wollner N, et al. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease. Blood 1996;87:2905-17.
20. Gianotti R, Alessi E, Cavicchini S, Berti E. Primary cutaneous pleomorphic lymphoma expressing CD30 antigen. Am J Dermatopathol 1991;13:503-8.
21. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
22. Jaffe ES, Chan JKC. Introduction to the WHO classification: T and NK cell neoplasms. Am J Surg Pathol 1996;21:114-21.
23. Kadin ME, Sako D, Berliner N, et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood 1986;68:1042-9.
24. Kaudewitz P, Dallenbach SF, Eckert F, Bieber K, Burg G, Braun-Falco O. Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large-cell lymphomas. Am J Pathol 1989;135:359-67.
25. Kurtin PJ, DiCaudo DJ, Habermann TM, Chen MG, Su D. Primary cutaneous large cell lymphomas: morphologic, immunophenotypic, and clinical features of 20 cases. Am J Surg Pathol 1994; 18:1183-91.
26. Lamant L, Meggetto F, Al Saati T, et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, RT-PCR and p80 immunostaining. Blood 1996;87:284-91.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
28. Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85:2528-36.
29. Liu Y, Hernandez AM, Shibata D, Cortopassi G. Bcl2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994;91:8910-2.
30. Lopategui JR, Sun LH, Chan JKC, et al. Low frequency association of the t(2;5)(p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. Am J Pathol 1995; 146:323-8.
31. MacGregor JM, Dublin EA, Levison DA, MacDonald DM, Smith NP, Whittaker S. p53 immunoreactivity is uncommon in primary cutaneous lymphoma. Br J Dermatol 1995;132:353-8.
32. MacGrogan G, Vergier B, Dubus P, et al. CD 30+ cutaneous lymphoma: a clinico-pathological and molecular study of 17 cases. Am J Clin Pathol 1996;105:440-50.
33. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995;13:1343-54.
34. Peris K, Niedermeyer H, Chimenti S, Radaskieweicz T, Kerl H, Hoefler H. Detection of Epstein Barr virus in cutaneous and lymph nodal anaplastic large cell lymphoma (Ki-1+). Br J Dermatol 1995;133:542-6.
35. Pinkus GS, Thomas P, Said JW. LeuM1-A marker for Reed-Sternberg cells in Hodgkin's disease: an immunoperoxidase study of paraffin-embedded tissues. Am J Pathol 1985;119:244-52.
36. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic-lymphoma-kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997;89:1394-404.
37. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994;12: 899-908.
38. Saati TA, Tkaczuk J, Krissansen G, et al. A novel antigen detected by the CBF.78 antibody further distinguishes anaplastic large cell lymphoma from Hodgkin's disease. Blood 1995;86:2741-6.
39. Sarris AH, Luthra R, Papadimitracopoulou V, et al. Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma but not in other non-Hodgkin's lymphomas, Hodgkin's disease or lymphomatoid papulosis. Blood 1996;88:1771-9.
40. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80 NPM/ ALK: a distinct clinicopathologic entity. Blood 1995;86:1954-60.
41. Tomaszewski MM, Lupton GP, Krishnan J, May DL. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30-positive anaplastic large cell lymphoma. J Cutan Pathol 1995;22: 310-8.
42. Trumper L, Daus H, Bonin F, Loftin U, Küpper M. Pfreundschuh M. NPM/ALK fusion mRNA expression occurs in peripheral blood B-lymphocytes of healthy donors as evidenced by reverse transcriptase polymerase chain reaction (RT-PCR). Blood 1996; 88:225a.
43. Wellmann A, Otsuki T, Vogelbruch M, Clark HM, Jaffe ES, Raffeld M. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Blood 1995;86:2321-8.
44. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferations disorders. J Am Acad Dermatol 1993;28:973-80.
45. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
46. Willemze R, Meyer CJLM, Van Vloten WA, Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dennatol 1982;107:131-44.
47. Wood GS, Hardman DL, Boni R, et al. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood 1996;88:1765-70.